The trial showed a response rate of 75% for those treated with AS1404 plus chemotherapy compared with 63% for patients receiving chemotherapy alone. The addition of AS1404 to chemotherapy was well tolerated.
Improvements in efficacy endpoints have now been observed in three separate phase II trials of AS1404 including trials for lung and prostate cancer.
The phase II studies in ovarian and prostate cancers are ongoing and will report further data on time to progression and survival over the coming year. The lung cancer trial is complete and Antisoma is now preparing for phase III development in this indication.
“We are very pleased with the pattern of data coming out of our phase II studies on AS1404. Ovarian cancer is a significant disease in its own right, and this latest news also adds further support to the idea that AS1404 has broad potential across a wide range of tumor types,” commented Glyn Edwards, CEO of Antisoma.